Literature DB >> 29238516

Antidiabetic medications and mortality reduction: a shift from surrogate to clinical endpoints.

Fariha Hasan1, Bilal Hasan2.   

Abstract

Year:  2017        PMID： 29238516      PMCID： PMC5721968          DOI： 10.1177/2042018817737955

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN： 2042-0188            Impact factor:   3.565


× No keyword cloud information.
  9 in total

1.  Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators.

Authors:  Elisabeth Svensson; Lisbeth M Baggesen; Søren P Johnsen; Lars Pedersen; Helene Nørrelund; Esben S Buhl; Christiane L Haase; Reimar W Thomsen
Journal:  Diabetes Care       Date:  2017-04-12       Impact factor: 19.112

2.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

Authors:  Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir
Journal:  N Engl J Med       Date:  2017-04-13       Impact factor: 91.245

3.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

Review 4.  Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.

Authors:  Dario Rahelić; Eugen Javor; Tomo Lucijanić; Marko Skelin
Journal:  Ann Med       Date:  2016-09-22       Impact factor: 4.709

Review 5.  Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.

Authors:  Srikanth Yandrapalli; George Jolly; Adam Horblitt; Abdallah Sanaani; Wilbert S Aronow
Journal:  Postgrad Med       Date:  2017-07-27       Impact factor: 3.840

6.  Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?

Authors:  Francesco Giorgino; Philip D Home; Jaakko Tuomilehto
Journal:  Diabetes Care       Date:  2016-08       Impact factor: 19.112

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.

Authors:  Guntram Schernthaner; Marie Helene Schernthaner-Reiter; Gerit-Holger Schernthaner
Journal:  Clin Ther       Date:  2016-05-19       Impact factor: 3.393

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.